Compare Booking Holdings Inc (BKNG) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booking Holdings Inc vs Enveric Biosciences Inc — how do they compare? Booking Holdings Inc trades at $211.63 (market cap $159.95B), while Enveric Biosciences Inc trades at $1.45 (market cap $6.20M). The key difference: Booking Holdings Inc is far larger — about 25798.4× Enveric Biosciences Inc's market cap, and Booking Holdings Inc pays a 0.79% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| BKNG | ENVB | |
|---|---|---|
Market Cap | $159.95B | $6.20M |
Sector | Consumer Cyclical | Health |
52-Week High | $228.83 | $17.40 |
52-Week Low | $154.13 | $1.27 |
Enterprise Value | $163.43B | $1.30M |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BKNG trades at $214.42, up 3.39% on strong Q2 2026 earnings beats, with bullish technical signals and a consensus price target of $239.31. Revenue growth accelerated to $26.92B in 2025, though net income dipped to $5.40B. The stock shows robust profitability with a 25.53% net margin and high ROE, but faces geopolitical and competitive pressures.
Outlook remains positive with resilient travel demand and AI integration driving efficiency, but risks include Middle East volatility and high debt levels. Analysts are overwhelmingly bullish with 64% buy ratings, supporting upside potential amid near-term headwinds.
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Booking Holdings Inc
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
